Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series

The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that are commonly available in general clinical practice.

Detalles Bibliográficos
Autores principales: Koba, Hayato, Yoneda, Taro, Kaneda, Tomoya, Ueda, Tsukasa, Kimura, Hideharu, Kasahara, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537071/
https://www.ncbi.nlm.nih.gov/pubmed/33042544
http://dx.doi.org/10.1002/ccr3.3358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537071/
https://www.ncbi.nlm.nih.gov/pubmed/33042544
http://dx.doi.org/10.1002/ccr3.3358

Ejemplares similares